PMC 002R
Alternative Names: Anti-KDR/TIE2 bispecific antibody - PharmAbcine; Anti-VEGFR2/TIE2 bispecific antibody - PharmAbcine; PMC-002RLatest Information Update: 28 Apr 2023
At a glance
- Originator PharmAbcine
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action TIE-2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in South Korea (IV, Injection)
- 08 Mar 2019 Preclinical trials in Cancer in South Korea before March 2019 (IV)
- 08 Mar 2019 PharmAbcine intends to submit an IND application for phase I trial in Cancer in the US